MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) CEO Douglas Doerfler sold 27,862 shares of the company’s stock in a transaction on Thursday, April 6th. The stock was sold at an average price of $5.03, for a total transaction of $140,145.86. Following the completion of the sale, the chief executive officer now owns 333,197 shares of the […]
MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) CEO Douglas Doerfler sold 7,470 shares of the company’s stock in a transaction that occurred on Tuesday, April 4th. The shares were sold at an average price of $5.03, for a total value of $37,574.10. Following the completion of the transaction, the chief executive officer now directly owns 333,197 […]
MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) shares were up 5.4% on Tuesday . The stock traded as high as $5.07 and last traded at $5.05. Approximately 240,222 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 569,156 shares. The stock had previously closed at $4.79. Wall Street Analyst […]
MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) EVP Thomas M. Ross sold 2,607 shares of MaxCyte stock in a transaction on Friday, March 31st. The stock was sold at an average price of $5.00, for a total transaction of $13,035.00. Following the transaction, the executive vice president now directly owns 333,197 shares in the company, valued […]
MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) Director Richard Douglas acquired 80,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 29th. The stock was bought at an average price of $4.32 per share, with a total value of $345,600.00. Following the transaction, the director now directly owns 100,000 shares in the […]